Abstract: An animation file processing method and apparatus, a computer-readable storage medium, and a computer device are provided. The method includes: obtaining a bitmap image sequence corresponding to an original animation file; encoding a differential pixel region between a bitmap image in the bitmap image sequence and a corresponding key bitmap image when the bitmap image is a non-key bitmap image, to obtain an encoded picture corresponding to the bitmap image; and generating an animation export file corresponding to the original animation file according to encoded pictures corresponding to bitmap images in the bitmap image sequence.

Abstract: A packaging structure of a film bulk acoustic resonator includes a resonant cavity main structure that includes a first substrate and a film bulk acoustic resonant structure over the first substrate with a first cavity formed there-between. A resonator cover includes a second substrate and an elastic bonding material layer that has lost elasticity and is sandwiched between the second substrate and the film bulk acoustic resonant structure. The elastic bonding material layer contains a second cavity, and the second cavity is at least partially aligned with the first cavity. A through-hole is formed through the resonator cover on a periphery of the second cavity and exposes a corresponding electrical connection part of the film bulk acoustic resonant structure. A conductive interconnection layer covers a sidewall of the through-hole and a portion of a surface of the resonator cover on a periphery of the through-hole.

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

Abstract: The present disclosure relates to the field of medical technology, and in particular to a composition and the use thereof in the manufacture of a medicament for treating cancer. The present disclosure provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. The present disclosure shows through in vivo and in vitro anti-tumor tests that, based on the inhibitory effect of the tyrosine kinase activity inhibitor targeting VEGFR, EGFR and other receptor tyrosine kinases, the combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.

Abstract: The present disclosure relates to the field of medical technology, and in particular to use of a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof in the manufacture of a medicament for treating cancer. By testing the inhibitory effect on a variety of tumor cells, the results show that the compound of formula I has an inhibitory effect on tumor cells, with an IC50 of 40.77 ?M-182.5 ?M. In animal experiments, the compound of formula I shows a good inhibition effect on tumor volume, which is very significantly different from that of the solvent control group, p<0.05.

Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.

Abstract: Provided are a memory lymphocyte population, a culture medium, and a method for obtaining the memory lymphocyte population and a use of the same. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.